Millrace Asset Group Inc. Takes Position in BioScrip Inc (BIOS)

Millrace Asset Group Inc. acquired a new stake in BioScrip Inc (NASDAQ:BIOS) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 430,249 shares of the company’s stock, valued at approximately $1,058,000. Millrace Asset Group Inc. owned approximately 0.34% of BioScrip at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BIOS. Gotham Asset Management LLC acquired a new position in BioScrip in the fourth quarter valued at $114,000. MetLife Investment Advisors LLC acquired a new position in BioScrip in the fourth quarter valued at $174,000. Two Sigma Advisers LP boosted its stake in BioScrip by 100.4% in the fourth quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock valued at $373,000 after acquiring an additional 64,238 shares in the last quarter. Wells Fargo & Company MN boosted its stake in BioScrip by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 217,450 shares of the company’s stock valued at $634,000 after acquiring an additional 55,636 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in BioScrip in the first quarter valued at $635,000. Institutional investors own 85.46% of the company’s stock.

Several research firms have issued reports on BIOS. BidaskClub downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Wednesday, May 23rd. Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Tuesday, May 15th. Craig Hallum restated a “buy” rating and issued a $3.50 price objective on shares of BioScrip in a research note on Thursday, March 8th. Finally, SunTrust Banks reiterated a “buy” rating and set a $3.25 target price on shares of BioScrip in a research note on Thursday, March 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $3.45.

Shares of BIOS opened at $2.54 on Wednesday. BioScrip Inc has a fifty-two week low of $1.80 and a fifty-two week high of $3.39. The stock has a market cap of $325.00 million, a PE ratio of -5.77 and a beta of 0.08. The company has a debt-to-equity ratio of -4.79, a current ratio of 1.70 and a quick ratio of 1.30.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, May 10th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The firm had revenue of $168.60 million for the quarter, compared to analyst estimates of $164.72 million. During the same period last year, the business earned ($0.18) EPS. The business’s revenue for the quarter was down 22.6% on a year-over-year basis. sell-side analysts anticipate that BioScrip Inc will post -0.31 EPS for the current year.

BioScrip Company Profile

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip Inc (NASDAQ:BIOS).

Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply